May 27, 2026
Written By
Michael Minh Le
Subscribe to the Premed Catalyst Newsletter
You're staring at your school list, trying to figure out if Icahn School of Medicine at Mount Sinai deserves a spot on it. Maybe someone told you it's a powerhouse. Maybe you're not sure if your stats are competitive enough. Either way, you need a real answer, not a vague "it's a great school" that tells you nothing about whether it's the right school for you.
This article breaks down exactly where Icahn stands in 2026 across U.S. News rankings, global university rankings, and research output. We'll look at whether the school is trending up or down, what those rankings are actually measuring, and, most importantly, whether any of it should factor into your decision at all.
Here's the thing, though: rankings are only part of the picture. A school's position on a list means nothing if you can't build an application that actually gets you in. That’s why we put together a free Application Database with 8 real AMCAS applications that earned acceptances to top medical schools, including personal statements, most meaningful entries, and full activity descriptions.
Get unlimited access here.
Rankings are one of the first things premeds look into when they're building their school list. Here's exactly where Icahn stands in 2026.
Starting with the 2024 rankings, U.S. News moved away from ordinal numbered rankings and switched to a four-tier system. Schools are now grouped within tiers rather than assigned an individual number.
Icahn voluntarily withdrew from the U.S. News rankings process. Icahn's leadership stated that the rankings provide a flawed and misleading assessment, lack accuracy and validity, and undermine core commitments to compassionate care, research, and outreach to diverse communities.
Because of that, Icahn is currently listed as "Unranked" in both the Best Medical Schools: Research and Best Medical Schools: Primary Care categories.
Before they withdrew, when the U.S. News still published numerical rankings, Icahn held a rank of #11 in Research. Their historical Primary Care numerical rank isn't consistently documented across verified sources because primary care was never their identity as a program.
On the global stage, QS ranks Icahn #60 in the world in its Subject Rankings for Medicine in 2026.
Where Icahn's global reputation really shows up is in the Nature Index, which measures actual publication output in the world's leading scientific journals, not surveys or reputation scores. The Nature Index ranked Icahn #128 among the top academic research institutions globally and #36 specifically in Health Sciences.
For a school with no undergraduate program and roughly 1,200 students total, competing at that level against full research universities with tens of thousands of students is something to take notice of.
This is where Icahn's reputation is actually built, and it's the section that should matter most to you if you're serious about going into medicine to push the field forward. Icahn ranks #11 nationally for NIH funding, receiving $501.7 million from the NIH in the most recent federal fiscal year, placing it in the 99th percentile among private U.S. medical schools in research dollars per investigator.
And that's just NIH. Total research funding across the institution hit $875 million in calendar year 2025.
Zoom into the department level, and the numbers get even more specific. Thirteen basic and clinical science departments rank in the top 20 for NIH funding nationwide, with Pharmacology ranked #1, Neuroscience #2, Dermatology, Microbiology, and Psychiatry each at #3, and Public Health at #4.
On the U.S. News medical school rankings, Icahn is listed as "Unranked" in both Research and Primary Care, and that number isn't going to change, because the school made a deliberate decision to stop submitting data. That's not a fall. That's an exit.
On the global stage, the trajectory is clearly upward. QS ranked Icahn #60 globally in Medicine for 2026, up from #89 in 2025 and #128 in 2024.
The NIH funding picture tells the same story. Twelve departments moved up in the NIH funding standings in 2025 alone, and Icahn held its overall position at #11 nationally. The Department of Pharmacology climbed from #2 to #1 in that same period. These are departments competing against every major research university in the country, not just other medical schools.
The Nature Index and the U.S. News Best Global Universities ranking, where Icahn sits at #40 in the world, have both remained strong and consistent. These rankings measure research impact through citations and publication output in elite journals, which means they're harder to game and slower to shift. Icahn holding firm in both is a signal of institutional stability at the top, not stagnation.
Rankings are numbers. Numbers need context. Before you let a tier placement or a global position tell you where to apply, you need to know what these systems are actually rewarding, and what they're completely blind to.
Different systems measure completely different things, and conflating them is one of the most common mistakes premeds make when building their school list.
U.S. News built its Research ranking around factors like:
The Primary Care ranking primarily uses the percentage of graduates entering primary care residencies.
QS Subject Rankings are built differently. They weigh academic reputation surveys among researchers and employers globally, research citations per faculty member, and the ratio of faculty to students. It's a reputation-and-output hybrid, meaning it captures how the international academic community perceives an institution and how productive its researchers are.
The Nature Index is the most straightforward of the group. It counts publications in a curated set of high-quality natural science journals. No surveys, no reputation scores, no input from administrators. You either published in a top journal or you didn't. That's it.
NIH funding rankings measure how much federal research money a school's investigators are winning in open competition. This is peer-reviewed grant funding where other scientists evaluated the proposals and decided they were worth funding.
Here's what none of them measure, and this is the part that actually determines whether medical school should make it on your school list or not.
Rankings don't measure teaching quality. A faculty member can be a world-class researcher and a terrible teacher. The two are not the same thing, and no ranking system distinguishes between them.
They don't measure student support. How the school treats you when you fail an exam, when you're burned out, when you're questioning whether medicine is right for you, none of that shows up in any of these numbers.
They don't measure match outcomes in your specific specialty. A school can rank #11 in research and send zero students into neurosurgery in a given year. Or it can be ranked outside the top 20 and have a pipeline straight into competitive dermatology programs because of specific faculty relationships.
They don't measure diversity of clinical exposure. Eight hospitals and ten million people in the New York metro area mean Icahn students see pathology that simply doesn't exist in smaller markets. That kind of clinical volume and complexity doesn't appear in any ranking methodology, but it is the difference between a student who has seen everything by third year and one who hasn't.
Rankings are a starting point, but they don't tell you whether that school is the right place for you to spend the four most formative years of your professional life.
Premeds love to compare schools against each other. That's fine, but you need to be comparing the right things. Here's how Icahn actually stacks up against the schools it's most frequently compared to, using the metrics that matter.
Against the national elite. UCSF holds the top spot for NIH funding, taking in approximately $724 million in fiscal year 2025. That's the benchmark at the very top. Icahn sits at #11 nationally with $501.7 million in NIH funding, which puts it in the same conversation as schools like Duke, Northwestern, and UCLA, and ahead of institutions with far more famous names. The schools above Icahn on the NIH list are not surprises: UCSF, Johns Hopkins, Harvard, Penn, Washington University, Yale.
Against its New York neighbors. This is where it gets interesting. NYU Grossman is ranked #2 for Research according to U.S. News, but NYU is still participating in that ranking system. Icahn opted out. NYU Langone reports $962 million in active NIH awards as of December 2025, which is a larger total, but that figure covers the entire health system and research enterprise, not the medical school alone.
In 2024, Columbia received $527 million in NIH funding, compared to Icahn's $460 million that same year, placing Columbia slightly ahead. Weill Cornell, for all its prestige and Upper East Side address, receives significantly less NIH funding than Icahn, a fact that surprises a lot of premeds who assume Cornell's brand automatically means Cornell's research output.
If you're asking whether rankings tell you Icahn is a legitimate, world-class medical school, then yes, they do. Every system that measures research output, funding, and global academic reputation puts Icahn in the top tier. You don't need to wonder whether this is a solid institution. It is. The ranking conversation around Icahn is not about quality. Quality is settled.
If you're asking whether the U.S. News "Unranked" label should scare you, then no. It shouldn't. And if it does, you need to understand why it happened before you let it influence your list. Icahn didn't fall out of the rankings. It walked out of them on purpose, alongside Harvard, Columbia, Stanford, and Penn, schools that don't need a magazine's validation to fill their classes with the best applicants in the country. The "Unranked" label is a statement about U.S. News methodology, not about Icahn.
If you're asking whether rankings should drive your decision to apply here, then this is where you need to slow down. The ranking doesn't tell you whether Icahn's culture fits you. It doesn't tell you whether you'll thrive in New York City, whether you'll connect with a mentor in the specific research area you care about, or whether the ASCEND curriculum matches the way you learn. Those things will have a bigger impact on your four years than any number in any publication.
Here's the real question you should be asking: Does Icahn give you access to the training, the research, the clinical volume, and the faculty relationships that make you the doctor you want to be?
You've done the research. You know where Icahn stands. But here's the part that actually determines whether any of this matters for you: you have to get in first.
That's why we built a free Application Database with 8 real AMCAS applications that earned acceptances to top medical schools. Full personal statements. Most meaningful entries. Complete activity descriptions. Including my own UCLA application.
If you're serious about building a list that includes schools like Icahn, the next step isn't more research into rankings. It's understanding what a successful application actually looks like so you can build yours with your eyes open.
Get your free resource here.
